SEP 7, 2026 · JOURNAL ARTICLE
RUNX2 inhibitor CADD522 improves bone microarchitecture and lipid metabolism in post-menopausal bone loss
npj Drug Discovery.
Preclinical mechanistic study in an animal model with no clinical trial data, demonstrating target engagement and a potential therapeutic approach requiring confirmation in human subjects.
Reported
Dose and dosing frequency25 mg/kg, three times weekly for eight weeks
ModelOvariectomy-induced mouse model